{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:24:09Z","timestamp":1787387049231,"version":"build-2736575974"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100002429","name":"Amgen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002429","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s12325-026-03659-4","type":"journal-article","created":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T19:21:04Z","timestamp":1782847264000},"page":"4282-4298","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer\u00a0"],"prefix":"10.1007","volume":"43","clinical-trial-number":[{"clinical-trial-number":"nct05740566","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Franziska","family":"Dirnberger","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sachin","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devon J.","family":"Boyne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhiyi","family":"Lan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Uyei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seoyoon","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucy","family":"DeCosta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M.","family":"Bridges","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3906-3004","authenticated-orcid":false,"given":"Umit","family":"Tapan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,6,30]]},"reference":[{"issue":"28","key":"3659_CR1","doi-asserted-by":"publisher","first-page":"4539","DOI":"10.1200\/JCO.2005.04.4859","volume":"24","author":"R Govindan","year":"2006","unstructured":"Govindan R, Page N, Morgensztern D, et al. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol. 2006;24(28):4539\u201344.","journal-title":"J Clin Oncol"},{"issue":"4","key":"3659_CR2","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/S2213-2600(24)00428-4","volume":"13","author":"G Luo","year":"2025","unstructured":"Luo G, Zhang Y, Rumgay H, et al. Estimated worldwide variation and trends in incidence of lung cancer by histological subtype in 2022 and over time: a population-based study. Lancet Respir Med. 2025;13(4):348\u201363.","journal-title":"Lancet Respir Med"},{"issue":"3","key":"3659_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/cam4.70608","volume":"14","author":"D Uprety","year":"2025","unstructured":"Uprety D, Seaton R, Niroula A, Hadid T, Parikh K, Ruterbusch JJ. Trends in the incidence and survival outcomes in patients with small cell lung cancer in the United States: an analysis of the SEER database. Cancer Med. 2025;14(3):e70608.","journal-title":"Cancer Med"},{"issue":"3","key":"3659_CR4","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S0169-5002(02)00072-7","volume":"37","author":"P Micke","year":"2002","unstructured":"Micke P, Faldum A, Metz T, et al. Staging small cell lung cancer: Veterans Administration Lung Study Group versus International Association for the Study of Lung Cancer\u2014what limits limited disease? Lung Cancer. 2002;37(3):271\u20136.","journal-title":"Lung Cancer"},{"issue":"9","key":"3659_CR5","doi-asserted-by":"publisher","first-page":"2945","DOI":"10.7150\/jca.75622","volume":"13","author":"B Oronsky","year":"2022","unstructured":"Oronsky B, Abrouk N, Caroen S, et al. A 2022 update on extensive stage small-cell lung cancer (SCLC). J Cancer. 2022;13(9):2945\u201353.","journal-title":"J Cancer"},{"key":"3659_CR6","volume":"6","author":"O Abughanimeh","year":"2020","unstructured":"Abughanimeh O, Ernani V, Marr A, Ganti AK. Current updates in management of relapsed\/refractory small cell lung cancer. J Cancer Metastasis Treat. 2020;6:50.","journal-title":"J Cancer Metastasis Treat"},{"issue":"13","key":"3659_CR7","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1016\/j.ejca.2014.06.002","volume":"50","author":"A Ardizzoni","year":"2014","unstructured":"Ardizzoni A, Tiseo M, Boni L. Validation of standard definition of sensitive versus refractory relapsed small cell lung cancer: a pooled analysis of topotecan second-line trials. Eur J Cancer. 2014;50(13):2211\u20138.","journal-title":"Eur J Cancer"},{"issue":"7","key":"3659_CR8","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1016\/j.annonc.2021.03.207","volume":"32","author":"AC Dingemans","year":"2021","unstructured":"Dingemans AC, Fr\u00fch M, Ardizzoni A, et al. Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up(\u2606). Ann Oncol. 2021;32(7):839\u201353.","journal-title":"Ann Oncol"},{"key":"3659_CR9","unstructured":"Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft DK, AWMF),. Pr\u00e4vention, Diagnostik, Therapie und Nachsorge des Lungenkarzinoms, Lang-version 4.0, 2025, AWMF-Registernummer: 020\u2013007OL. 2025."},{"issue":"2","key":"3659_CR10","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.cllc.2014.10.002","volume":"16","author":"R Gervais","year":"2015","unstructured":"Gervais R, Le Caer H, Monnet I, et al. Second-line oral chemotherapy (lomustine, cyclophosphamide, etoposide) versus intravenous therapy (cyclophosphamide, doxorubicin, and vincristine) in patients with relapsed small cell lung cancer: a randomized phase II study of GFPC 0501. Clin Lung Cancer. 2015;16(2):100\u20135.","journal-title":"Clin Lung Cancer"},{"issue":"2","key":"3659_CR11","doi-asserted-by":"publisher","first-page":"274","DOI":"10.1016\/j.jtho.2019.10.013","volume":"15","author":"TK Owonikoko","year":"2020","unstructured":"Owonikoko TK, Niu H, Nackaerts K, et al. Randomized phase II study of paclitaxel plus alisertib versus paclitaxel plus placebo as second-line therapy for SCLC: primary and correlative biomarker analyses. J Thorac Oncol. 2020;15(2):274\u201387.","journal-title":"J Thorac Oncol"},{"issue":"35","key":"3659_CR12","doi-asserted-by":"publisher","first-page":"4012","DOI":"10.1200\/JCO.2013.54.5392","volume":"32","author":"J von Pawel","year":"2014","unstructured":"von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of amrubicin versus topotecan as second-line treatment for patients with small-cell lung cancer. J Clin Oncol. 2014;32(35):4012\u20139.","journal-title":"J Clin Oncol"},{"key":"3659_CR13","doi-asserted-by":"publisher","first-page":"2063","DOI":"10.1056\/NEJMoa2307980","volume":"389","author":"M-J Ahn","year":"2023","unstructured":"Ahn M-J, Cho BC, Felip E, et al. Tarlatamab for patients with previously treated small-cell lung cancer. N Engl J Med. 2023;389:2063\u201375.","journal-title":"N Engl J Med"},{"key":"3659_CR14","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa2502099","author":"G Mountzios","year":"2025","unstructured":"Mountzios G, Sun L, Cho BC, et al. Tarlatamab in small-cell lung cancer after platinum-based chemotherapy. N Engl J Med. 2025. https:\/\/doi.org\/10.1056\/nejmoa2502099.","journal-title":"N Engl J Med"},{"key":"3659_CR15","doi-asserted-by":"crossref","unstructured":"Blackhall F, Wang J, Takundwa R, et al. Network meta-analysis NMA of clinical effectiveness of second-line (2L+) Treatments in extensive-stage small cell lung cancer (ES-SCLC). ISPOR Europe 2025, Glasgow, Scotland. 2025.","DOI":"10.1016\/j.jval.2025.09.271"},{"issue":"12","key":"3659_CR16","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.6004\/jnccn.2021.0058","volume":"19","author":"AKP Ganti","year":"2021","unstructured":"Ganti AKP, Loo BW, Bassetti M, et al. Small cell lung cancer, version 2.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2021;19(12):1441\u201364.","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"3659_CR17","doi-asserted-by":"publisher","first-page":"6078","DOI":"10.1007\/s12325-025-03376-4","volume":"42","author":"R Takundwa","year":"2025","unstructured":"Takundwa R, Suri G, Dirnberger F, et al. Matching-adjusted indirect treatment comparison of tarlatamab versus comparator therapies in england in patients with extensive-stage small cell lung cancer who have received two or more prior lines of therapy. Adv Ther. 2025;42(12):6078\u201390.","journal-title":"Adv Ther"},{"issue":"18","key":"3659_CR18","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.2217\/cer-2020-0134","volume":"9","author":"ST Keeping","year":"2020","unstructured":"Keeping ST, Cope S, Chan K, et al. Comparative effectiveness of nivolumab versus standard of care for third-line patients with small-cell lung cancer. J Comp Eff Res. 2020;9(18):1275\u201384.","journal-title":"J Comp Eff Res"},{"issue":"5","key":"3659_CR19","doi-asserted-by":"publisher","DOI":"10.57264\/cer-2022-0098","volume":"12","author":"R Hanvesakul","year":"2023","unstructured":"Hanvesakul R, Rengarajan B, Naveh N, et al. Indirect treatment comparison of lurbinectedin versus other second-line treatments for small-cell lung cancer. J Comp Eff Res. 2023;12(5):e220098.","journal-title":"J Comp Eff Res"},{"key":"3659_CR20","volume-title":"Tarlatamab (Imdelltra): therapeutic area: extensive-stage small cell lung cancer: reimbursement review","author":"CADTH Reimbursement Reviews and Recommendations","year":"2025","unstructured":"CADTH Reimbursement Reviews and Recommendations. Tarlatamab (Imdelltra): therapeutic area: extensive-stage small cell lung cancer: reimbursement review. Ottawa: Canadian Agency for Drugs and Technologies in Health; 2025."},{"issue":"9","key":"3659_CR21","doi-asserted-by":"publisher","first-page":"oyaf256","DOI":"10.1093\/oncolo\/oyaf256","volume":"30","author":"J Wang","year":"2025","unstructured":"Wang J, Sajeev G, Chai X, et al. Efficacy outcomes between tarlatamab and real-world physicians\u2019 choice of therapies for previously treated extensive stage small cell lung cancer. Oncologist. 2025;30(9):oyaf256.","journal-title":"Oncologist"},{"key":"3659_CR22","unstructured":"Marin F, Rohatgi A, Charlot S. WebPlotDigitizer, a polyvalent and free software to extract spectra from old astronomical publications: application to ultraviolet spectropolarimetry. arXiv preprint arXiv:170802025. 2017."},{"key":"3659_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-12-9","volume":"12","author":"P Guyot","year":"2012","unstructured":"Guyot P, Ades AE, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012;12:9.","journal-title":"BMC Med Res Methodol"},{"key":"3659_CR24","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. NICE DSU technical support document 18: methods for population-adjusted indirect comparisons in submission to NICE. 2016."},{"issue":"25","key":"3659_CR25","doi-asserted-by":"publisher","first-page":"3083","DOI":"10.1002\/sim.3697","volume":"28","author":"PC Austin","year":"2009","unstructured":"Austin PC. Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples. Stat Med. 2009;28(25):3083\u2013107.","journal-title":"Stat Med"},{"issue":"8","key":"3659_CR26","doi-asserted-by":"publisher","first-page":"849","DOI":"10.1016\/j.jclinepi.2006.11.003","volume":"60","author":"SD Walter","year":"2007","unstructured":"Walter SD, Yao X. Effect sizes can be calculated for studies reporting ranges for outcome variables in systematic reviews. J Clin Epidemiol. 2007;60(8):849\u201352.","journal-title":"J Clin Epidemiol"},{"issue":"4","key":"3659_CR27","doi-asserted-by":"publisher","first-page":"268","DOI":"10.7326\/M16-2607","volume":"167","author":"TJ VanderWeele","year":"2017","unstructured":"VanderWeele TJ, Ding P. Sensitivity analysis in observational research: introducing the E value. Ann Intern Med. 2017;167(4):268\u201374.","journal-title":"Ann Intern Med"},{"key":"3659_CR28","doi-asserted-by":"publisher","DOI":"10.1186\/1471-2288-13-152","volume":"13","author":"P Royston","year":"2013","unstructured":"Royston P, Parmar MK. Restricted mean survival time: an alternative to the hazard ratio for the design and analysis of randomized trials with a time-to-event outcome. BMC Med Res Methodol. 2013;13:152.","journal-title":"BMC Med Res Methodol"},{"issue":"20","key":"3659_CR29","doi-asserted-by":"publisher","first-page":"3832","DOI":"10.1002\/sim.8206","volume":"38","author":"SC Conner","year":"2019","unstructured":"Conner SC, Sullivan LM, Benjamin EJ, LaValley MP, Galea S, Trinquart L. Adjusted restricted mean survival times in observational studies. Stat Med. 2019;38(20):3832\u201360.","journal-title":"Stat Med"},{"key":"3659_CR30","unstructured":"Member State Coordination Group on Health Technology Assessment (HTA CG). Methodological guideline for quantitative evidence synthesis: direct and indirect comparisons. 2024. https:\/\/health.ec.europa.eu\/."},{"issue":"2","key":"3659_CR31","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1177\/0272989X17725740","volume":"38","author":"DM Phillippo","year":"2018","unstructured":"Phillippo DM, Ades AE, Dias S, Palmer S, Abrams KR, Welton NJ. Methods for population-adjusted indirect comparisons in health technology appraisal. Med Decis Making. 2018;38(2):200\u201311.","journal-title":"Med Decis Making"},{"issue":"2","key":"3659_CR32","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1093\/ije\/dyac018","volume":"51","author":"A Sj\u00f6lander","year":"2022","unstructured":"Sj\u00f6lander A, Greenland S. Are E values too optimistic or too pessimistic? Both and neither! Int J Epidemiol. 2022;51(2):355\u201363.","journal-title":"Int J Epidemiol"},{"key":"3659_CR33","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.2147\/CLEP.S546282","volume":"17","author":"X Pundole","year":"2025","unstructured":"Pundole X, Younan D, Critchlow CW, et al. A multi-country study of the clinical course of extensive-stage small cell lung cancer: a six-study analysis of real-world treatment patterns and outcomes. Clin Epidemiol. 2025;17:1117\u201329.","journal-title":"Clin Epidemiol"},{"issue":"12","key":"3659_CR34","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1093\/oncolo\/oyae234","volume":"29","author":"J Shaw","year":"2024","unstructured":"Shaw J, Pundole X, Balasubramanian A, et al. Recent treatment patterns and real-world survival following first-line anti-PD-L1 treatment for extensive-stage small cell lung cancer. Oncologist. 2024;29(12):1079\u201389.","journal-title":"Oncologist"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03659-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-026-03659-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-026-03659-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,22]],"date-time":"2026-08-22T08:04:51Z","timestamp":1787385891000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-026-03659-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,30]]},"references-count":34,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["3659"],"URL":"https:\/\/doi.org\/10.1007\/s12325-026-03659-4","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,30]]},"assertion":[{"value":"26 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Umit Tapan reports personal fees for consulting from Amgen. Franziska Dirnberger, Sachin Patel, Jessie Wang, Seoyoon Cho, Lucy DeCosta, and Ian Bridges are employees of Amgen and hold stock\/options. Devon Boyne, Zhiyi Lan, and Jenny Uyei are employees of IQVIA Inc. which received funding from Amgen Inc. for the conduct of this study.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study involved use of de-identified data from DeLLphi-304 and previously published aggregate-level summary statistics from Owonikoko 2020 and GFPC 0501, compliant with the United States (US) Health Insurance Portability and Accountability Act (HIPAA) and the Helsinki Declaration of 1964 and its later amendments or comparable ethical standards. The US Department of Health and Human Services does not consider analysis of de-identified secondary data to meet the definition for human subject research. Therefore, this study was exempt from federal regulations and did not require patient consent or institutional review board approval.","order":2,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}